| 标题 |
专利、报告等 Subgroup analysis of Chinese patients in a phase 3 study of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma
仑伐替尼vs索拉非尼一线治疗不可切除肝细胞癌患者的3期研究中国患者亚组分析
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Qin S OX, Bai Y, Cheng Y, Chen Z, Ren Z, Song T, Dutcus C, Saito K, Tamai T, Yau TCC, Rau K‐M, Cheng A‐L, Han G. Subgroup analysis of Chinese patients in a phase 3 study of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Hepatol Int 2019;13:S170. |
| 求助人 | |
| 下载 | 暂无链接，等待应助者上传 |
mmyhn
科研小民工
迟大猫
liudiqiu
Agernon
热心路人
SYLH
HEIKU
VDC
暴躁四叔
36456657
tuanheqi
Leon
冬水水
归尘
贰鸟
pcr163
Zn
坚强的广山
于芋菊
皖公网安备34019202002308
